Intellia Therapeutics
NTLA
157 hedge funds and large institutions have $833M invested in Intellia Therapeutics in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 53 reducing their positions, and 19 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
6% more capital invested
Capital invested by funds: $789M → $833M (+$43.6M)
1% more funds holding
Funds holding: 156 → 157 (+1)
0.41% more ownership
Funds ownership: 66.97% → 67.37% (+0.41%)
25% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 53
54% less call options, than puts
Call options by funds: $3.02M | Put options by funds: $6.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$36.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.37M |
| 3 |
BlackRock
New York
|
+$5.47M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$10.3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$8.44M |
| 4 |
Morgan Stanley
New York
|
-$7.69M |
| 5 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$6.44M |
NTLA Hedge Fund Activity: Q3 2018 in Review
157 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2018, worth a combined $833M — up 5.5% from $789M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NTLA positions and 19 closed out — a net gain of 2 holders — while 40 added to existing stakes and 53 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $36.1M. The largest seller was State Street, cutting an estimated $18.3M.
- 157 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2018, up from 156 in Q2 2018.
- Funds reported $833M of Intellia Therapeutics stock for Q3 2018, up 5.5% quarter-over-quarter.
- 21 funds opened new Intellia Therapeutics positions in Q3 2018 and 19 closed out, a net change of +2 holders.
- The largest Intellia Therapeutics buyer in Q3 2018 was ARK Investment Management, an estimated $36.1M added.
- The largest Intellia Therapeutics seller in Q3 2018 was State Street, an estimated $18.3M sold.
Based on aggregated 13F filings for Q3 2018.